시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
항체 위탁생산 시장 보고서(2025년)
Antibody Contract Manufacturing Global Market Report 2025
상품코드 : 1824332
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,501,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,396,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,292,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

항체 위탁생산 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 15.4%를 나타내 297억 9,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 연구개발비 증가, 이중특이성 및 다중특이성 항체의 확대, 항체약물 복합체(adcs)의 대두, 헬스케어 인프라 증가, 정부의 이니셔티브 증가 등에 기인한다고 생각됩니다. 예측 기간의 주요 동향으로는 디지털화 및 데이터 분석, 고급 업스트림 기술, 새로운 다운스트림 처리 기술, 지속가능성에 대한 노력, 개발 및 제조 수탁(CDMO) 등이 있습니다.

향후 5년간의 성장률 15.4%라고 하는 예측은 전회의 예측으로부터 0.2%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세장벽은 스위스와 아일랜드에서 조달하는 싱글유스 바이오리액터 및 크로마토그래피 시스템의 비용을 상승시키고, 항체 의약의 개발을 지연시키고, 개발 제조 수탁기관(CDMO)의 운영 비용을 상승시킴으로써 미국의 생물 제제 시장을 저해할 것으로 예측됩니다. 또한, 상호관세와 무역마찰의 격화와 제한에 의한 세계경제와 무역에 대한 악영향에 의해 그 영향은 보다 광범위하게 미칠 것으로 보입니다.

임상시험 건수 증가가 예상되기 때문에 향후 수년간은 항체 위탁생산 시장 성장이 전망됩니다. 임상시험은 새로운 치료와 개입, 진단방법의 안전성과 효능을 평가하기 위해 인간을 대상으로 실시되는 조사로, 항체 기반의 치료제나 진단제의 이용이 증가하고 있습니다. 이러한 급증은 임상시험을 위한 적시에 컴플라이언스에 적합한 공급을 보장하기 위한 고품질 항체에 대한 수요를 두드러지게 합니다. ClinicalTrials.gov의 2023년 5월 데이터에 따르면, 전 세계적으로 등록된 임상시험 수는 2022년 39만 9,499에서 2023년에는 43만 7,533으로 증가했으며, 이러한 시험의 약 53%가 미국 밖에서 등록되었습니다. 따라서 임상시험수 증가가 항체 위탁생산 시장 확대의 주요인이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Antibody contract manufacturing involves the outsourcing of antibody production and manufacturing to specialized contract manufacturing organizations (CMOs). These organizations possess the necessary expertise, infrastructure, and resources required for the manufacturing of antibodies on behalf of pharmaceutical and biotechnology companies.

The primary products of antibody contract manufacturing include monoclonal antibodies, polyclonal antibodies, and other antibody-related products. Monoclonal antibodies (mAbs) are specifically designed to target a particular antigen, and antibody contract manufacturing plays a crucial role in producing monoclonal antibodies on a large scale. This ensures consistent quality and quantity, meeting the demands for therapeutic or diagnostic applications. These antibodies are derived from sources such as mammals and microbes, and the manufacturing processes span preclinical, clinical, and commercial scales of operation. The end users of these antibody products include biopharmaceutical companies, research laboratories, and other entities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The antibody contract manufacturing research report is one of a series of new reports from The Business Research Company that provides antibody contract manufacturing market statistics, including the antibody contract manufacturing industry's global market size, regional shares, competitors with a antibody contract manufacturing market share, detailed antibody contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the antibody contract manufacturing industry. This antibody contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antibody contract manufacturing market size has grown rapidly in recent years. It will grow from $14.8 billion in 2024 to $16.79 billion in 2025 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to increased demand for monoclonal antibodies, shift towards personalized medicine, cost optimization, stringent regulatory requirements, globalization of biologics.

The antibody contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $29.79 billion in 2029 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to increasing r&d spending, expansion of bispecific and multispecific antibodies, rise of antibody-drug conjugates (adcs), increasing healthcare infrastructure, growing government initiatives. Major trends in the forecast period include digitalization and data analytics, advanced upstream technologies, novel downstream processing techniques, sustainability initiatives, contract development and manufacturing integration (CDMO).

The forecast of 15.4% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. biologics market by increasing the cost of single-use bioreactors and chromatography systems sourced from Switzerland and Ireland, thereby slowing antibody therapy development and elevating Contract Development and Manufacturing Organization(CDMO) operational costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in the number of clinical trials is poised to drive the growth of the antibody contract manufacturing market in the coming years. Clinical trials, which involve research studies conducted with human participants to assess the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures, are witnessing an increase in the utilization of antibody-based therapeutics or diagnostics. This surge accentuates the demand for high-quality antibodies to ensure a timely and compliant supply for clinical trials. According to ClinicalTrials.gov's May 2023 data, the number of registered clinical trial studies globally increased from 399,499 in 2022 to 437,533 in 2023, with around 53% of these studies registered outside the United States. Hence, the growing number of clinical trials is a key driver behind the expansion of the antibody contract manufacturing market.

The expected growth in the prevalence of chronic diseases is set to propel the antibody contract manufacturing market forward. Chronic diseases, characterized by their persistent and often progressive nature, require therapeutic antibodies for treatment. Antibody contract manufacturing plays a vital role in producing these therapeutic antibodies designed to target specific proteins or cells associated with chronic conditions, offering targeted and personalized treatment. With the U.S. population aged 50 and above projected to increase by 61.11% by 2050, and the prevalence of chronic diseases in this demographic nearly doubling, from 71.522 million in 2020 to an estimated 142.66 million by 2050, the demand for antibody contract manufacturing is expected to rise significantly.

Major companies in the antibody contract manufacturing market are concentrating on innovations such as single-use technology (SUT), which minimizes cross-contamination risks and reduces operational costs. SUT refers to disposable components and systems utilized in biopharmaceutical manufacturing processes. For instance, in September 2024, Merck & Co., a US-based pharmaceutical company, launched the Mobius ADC Reactor, aimed at enhancing the manufacturing of antibody-drug conjugates. This new single-use reactor significantly improves production efficiency by 70% compared to traditional stainless steel or glass methods. Its single-use design reduces cross-contamination risks and operational costs, enabling faster turnaround times. Additionally, advanced film technology enhances bag strength and leak resistance, ensuring the integrity of highly potent active pharmaceutical ingredients. This innovation supports biopharmaceutical companies in producing essential therapies more safely and efficiently.

Major companies in the antibody contract manufacturing market are focused on developing innovative solutions such as bispecific antibody platforms. These platforms play a pivotal role in the development of bispecific antibodies, utilizing scientific and technological approaches to create specialized antibodies. For instance, in September 2022, Samsung Biologics launched 'S-DUAL' and 'DEVELOPICK.' S-DUAL, a high-yield bispecific antibody platform, boasts a remarkable 99% success rate in chain pairing, optimizing manufacturing ease and achieving elevated titer and purity. DEVELOPICK, a rapid accessibility platform, enables the screening of molecules in early development, identifying candidates with optimal potential for progression to Investigational New Drug (IND) and Biological License Application (BLA). This comprehensive risk assessment platform empowers clients to evaluate drug candidates efficiently.

In April 2022, Asahi Kasei Medical Co., Ltd. acquired Bionova Scientific LLC for an undisclosed amount. This strategic acquisition expanded Asahi Kasei Medical's bioprocess business by incorporating a biopharmaceutical CDMO (contract development and manufacturing organization). Bionova Scientific LLC, a U.S.-based CDMO, specializes in developing and manufacturing recombinant protein products, including antibodies.

Major companies operating in the antibody contract manufacturing market include AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Fujifilm Holdings Corporation, Eurofins Scientific SE, Lonza Group AG, Labcorp Drug Development, Catalent Inc., Charles River Laboratories International Inc., Merck KGaA, Samsung Biologics Co. Ltd., Wuxi Biologics Cayman Inc, Siegfried Holding AG, Recipharm AB, Emergent BioSolutions Inc., Aenova Group, Cambrex Corporation, Aldevron LLC, Novasep Holding SAS, Synthon, KBI Biopharma Inc., Nitto Avecia Pharma Services Inc., Cytovance Biologics Inc., AGC Biologics S.p.A.

North America was the largest region in the antibody contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antibody contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The antibody contract manufacturing market includes revenues earned by entities by providing services such as cell line development, process optimization, and the manufacturing of clinical trial materials. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antibody Contract Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antibody contract manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for antibody contract manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The antibody contract manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Antibody Contract Manufacturing Market Characteristics

3. Antibody Contract Manufacturing Market Trends And Strategies

4. Antibody Contract Manufacturing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Antibody Contract Manufacturing Growth Analysis And Strategic Analysis Framework

6. Antibody Contract Manufacturing Market Segmentation

7. Antibody Contract Manufacturing Market Regional And Country Analysis

8. Asia-Pacific Antibody Contract Manufacturing Market

9. China Antibody Contract Manufacturing Market

10. India Antibody Contract Manufacturing Market

11. Japan Antibody Contract Manufacturing Market

12. Australia Antibody Contract Manufacturing Market

13. Indonesia Antibody Contract Manufacturing Market

14. South Korea Antibody Contract Manufacturing Market

15. Western Europe Antibody Contract Manufacturing Market

16. UK Antibody Contract Manufacturing Market

17. Germany Antibody Contract Manufacturing Market

18. France Antibody Contract Manufacturing Market

19. Italy Antibody Contract Manufacturing Market

20. Spain Antibody Contract Manufacturing Market

21. Eastern Europe Antibody Contract Manufacturing Market

22. Russia Antibody Contract Manufacturing Market

23. North America Antibody Contract Manufacturing Market

24. USA Antibody Contract Manufacturing Market

25. Canada Antibody Contract Manufacturing Market

26. South America Antibody Contract Manufacturing Market

27. Brazil Antibody Contract Manufacturing Market

28. Middle East Antibody Contract Manufacturing Market

29. Africa Antibody Contract Manufacturing Market

30. Antibody Contract Manufacturing Market Competitive Landscape And Company Profiles

31. Antibody Contract Manufacturing Market Other Major And Innovative Companies

32. Global Antibody Contract Manufacturing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antibody Contract Manufacturing Market

34. Recent Developments In The Antibody Contract Manufacturing Market

35. Antibody Contract Manufacturing Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기